Strategies to Coordinate the Multidisciplinary Team for Secondary Prevention, Long-Term Treatment, and the Assessment of Bleeding Risk
The New Era of Biosimilar Therapeutics for Multiple Sclerosis
Review of Clinical Trial and Real-World Data for DOAC and other Anticoagulation Therapeutics for VTE
Faculty Geoffrey Barnes, MD, MSc Associate Professor of Internal Medicine Vascular and Cardiovascular Medicine Director, Vascular Medicine Fellowship Frankel Cardiovascular Center University of Michigan Ann Arbor, MI
Update for Hospital and Health-System Pharmacists on Newer Therapeutics to Optimize Management of Patients with Generalized Myasthenia Gravis
Strategies to Address Unmet Needs and Care Delivery Disparities in the Management of Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease
Christine M. Chmielewski, CRNP Nephrology Nurse Practitioner Thomas Jefferson University Hospital Philadelphia, Pennsylvania Robert Provenzano, MD Associate Clinical Professor of Medicine Wayne State University School of Medicine Detroit, Michigan Disclosures of Relevant Financial Relationships It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this […]
Clinical Update for Individualized Treatment Plans for Patients with Generalized Myasthenia Gravis
Program Overview Patients with generalized myasthenia gravis (gMG) experience significant and heterogeneous symptomatology, placing a substantial burden on their quality of life including physical, emotional, and work/financial aspects. Recent clinical trial data are showing that the utilization of individualized dosing including holding treatment during periods of stability can be effective and safe. It is important […]
Accurate Diagnosis and Guideline-Driven Individualized Treatment Plans to Manage Patients with Non-Tuberculous Mycobacterial Lung Disease
Improving Systematic Monitoring for Glucocorticoid Adverse Events to Guide Appropriate Use of Steroid-Sparing Therapy in Patients with gMG
Program Overview Myasthenia gravis is one of the oldest recognized autoimmune neurologic diseases, but practice-changing clinical trials remain challenging despite greater knowledge of pathophysiology. Both incidence and prevalence of the disease have increased over the years because of greater awareness of MG, better application of diagnostic testing, and better quality of epidemiologic studies. Corticosteroids were introduced […]
Advances in Disease Management of Generalized Myasthenia Gravis
Program Overview This CME program will highlight recent advances in disease management of generalized myasthenia gravis (MG). The expert faculty, led by Dr. Vera Bril, will first outline the pathophysiology of myasthenia gravis, detailing epidemiology, pathogenesis and the case for targeted treatments. Following, current clinical trial data for FcRn inhibitors in MG will be analyzed, […]
Clinical Update on Anemia of Chronic Kidney Disease: Improving Outcomes for All Patients
